Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 7Urinary Bladder Neoplasms 4Carcinoma, Renal Cell 4Kidney Neoplasms 3Urethral Neoplasms 1Non-Metastatic Prostate Cancer 1Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter 1Locally Advanced Prostate Cancer 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 92Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 26Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Gefitinib × Genitourinary × Clear all
NCT00479089 2015-11-02

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
50 enrolled 5 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡